SARS-CoV-2-Specific T Cells Exhibit Phenotypic Feature Terminal Differentiation, and High Proliferation Potent

Cell Reports Medicine 1, 100081 DOI: 10.1016/j.xcrm.2020.100081

Citation Report

#	Article	IF	CITATIONS
1	T cell responses in patients with COVID-19. Nature Reviews Immunology, 2020, 20, 529-536.	22.7	706
2	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	27.0	936
3	SARS-CoV-2 Vaccine Development: Current Status. Mayo Clinic Proceedings, 2020, 95, 2172-2188.	3.0	96
4	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. Frontiers in Cellular and Infection Microbiology, 2020, 10, 575404.	3.9	4
5	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. Frontiers in Immunology, 2020, 11, 562264.	4.8	8
6	An Effective COVID-19 Vaccine Needs to Engage T Cells. Frontiers in Immunology, 2020, 11, 581807.	4.8	75
7	BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. Journal of Leukocyte Biology, 2021, 109, 49-53.	3.3	26
8	Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Research Reviews, 2021, 65, 101205.	10.9	601
9	T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical and Biophysical Research Communications, 2021, 538, 211-217.	2.1	88
10	HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes. International Journal of Infectious Diseases, 2021, 102, 163-169.	3.3	37
11	Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena valley. Epidemiology and Infection, 2021, 149, e194.	2.1	8
13	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science, 2021, 371, .	12.6	2,268
14	T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. Frontiers in Cellular and Infection Microbiology, 2021, 11, 624483.	3.9	110
15	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nature Communications, 2021, 12, 1162.	12.8	316
17	Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 2021, 184, 861-880.	28.9	1,364
18	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. ImmunoTargets and Therapy, 2021, Volume 10, 63-85.	5.8	40
21	Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?. Immunity and Ageing, 2021, 18, 12.	4.2	38
23	SARS-CoV-2–specific CD8+ T cell responses in convalescent COVID-19 individuals. Journal of Clinical Investigation, 2021, 131, .	8.2	213

ITATION REDO

CITATION REPORT

#	Article	IF	CITATIONS
24	Evidence of a dysregulated vitamin D endocrine system in SARS-CoV-2 infected patient's lung cells. Scientific Reports, 2021, 11, 8570.	3.3	11
25	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCl Insight, 2021, 6, .	5.0	52
27	Endothelial cell, myeloid, and adaptive immune responses in SARSâ€CoVâ€2 infection. FASEB Journal, 2021, 35, e21577.	0.5	13
28	Features of HLA class I expression and its clinical relevance in SARSâ€CoVâ€2: What do we know so far?. Reviews in Medical Virology, 2021, 31, e2236.	8.3	9
29	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microbial Cell Factories, 2021, 20, 88.	4.0	37
30	Antigenâ€dependent multistep differentiation of TÂfollicular helper cells and its role in SARSâ€CoVâ€⊋ infection and vaccination. European Journal of Immunology, 2021, 51, 1325-1333.	2.9	31
31	Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2. Frontiers in Immunology, 2021, 12, 660019.	4.8	15
32	Adaptive immune responses to SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 172, 1-8.	13.7	6
33	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. Archives of Pharmacal Research, 2021, 44, 499-513.	6.3	18
34	Immune profiling of COVID-19: preliminary findings and implications for the pandemic. , 2021, 9, e002550.		15
35	Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. Nature Communications, 2021, 12, 2593.	12.8	94
36	A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19. Frontiers in Immunology, 2021, 12, 674279.	4.8	5
37	Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity. Frontiers in Immunology, 2021, 12, 635942.	4.8	20
39	Relationship of SARS-CoV-2–specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. Journal of Clinical Investigation, 2021, 131, .	8.2	113
40	Alterations in T and B cell function persist in convalescent COVID-19 patients. Med, 2021, 2, 720-735.e4.	4.4	87
41	The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. International Immunopharmacology, 2021, 95, 107586.	3.8	26
42	The Role of Th17 Response in COVID-19. Cells, 2021, 10, 1550.	4.1	86
43	Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Reports, 2021, 36, 109414.	6.4	75

#	ARTICLE	IF	CITATIONS
44	SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathogens, 2021, 17, e1009761.	4.7	66
45	Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. Frontiers in Immunology, 2021, 12, 687449.	4.8	26
46	Insights into the virologic and immunologic features of SARS-COV-2. World Journal of Clinical Cases, 2021, 9, 5007-5018.	0.8	3
47	Detection of IFNÎ ³ -Secreting CD4+ and CD8+ Memory T Cells in COVID-19 Convalescents after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2. Viruses, 2021, 13, 1490.	3.3	18
48	Surviving Older Patients Show Preserved Cellular and Humoral Immunological Memory Several Months After SARS-CoV-2 Infection. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 33-40.	3.6	6
49	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature Reviews Immunology, 2021, 21, 475-484.	22.7	434
50	Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2. Life Sciences, 2021, 277, 119503.	4.3	17
51	Aging and CMV Infection Affect Pre-existing SARS-CoV-2-Reactive CD8+ T Cells in Unexposed Individuals. Frontiers in Aging, 2021, 2, .	2.6	16
52	Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells during Convalescence. Journal of Immunology, 2021, 207, 1344-1356.	0.8	14
53	Integrated single-cell analysis unveils diverging immune features of COVID-19, influenza, and other community-acquired pneumonia. ELife, 2021, 10, .	6.0	12
55	Breathing more breadth into COVID-19 TÂcell responses. Med, 2021, 2, 999-1001.	4.4	1
56	Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 731100.	4.8	32
57	T cell response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 2021, 16, e0245532.	2.5	228
58	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. Pathogens, 2021, 10, 138.	2.8	60
59	Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2–reactive CD8 ⁺ T cells. Science Immunology, 2021, 6, .	11.9	185
60	T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology, 2021, 2, iqaa007.	2.8	19
61	The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2. Current Opinion in HIV and AIDS, 2021, 16, 36-47.	3.8	6
69	Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. Journal of Clinical Investigation, 2020, 130, 6631-6638.	8.2	75

CITATION REPORT

#	Article	IF	CITATIONS
70	Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. ELife, 2020, 9, .	6.0	26
71	mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. ELife, 2021, 10, .	6.0	63
72	SARSâ€CoVâ€⊋ and lung injury: Dysregulation of immune response but not hyperimmune response as in "cytokine storm syndromeâ€: Clinical Respiratory Journal, 2022, 16, 13-16.	1.6	6
74	T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. Transplant Immunology, 2022, 70, 101495.	1.2	58
75	Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. Journal of Virology, 2022, 96, JVI0197321.	3.4	35
76	Single-Cell Immunogenomic Approach Identified SARS-CoV-2 Protective Immune Signatures in Asymptomatic Direct Contacts of COVID-19 Cases. Frontiers in Immunology, 2021, 12, 733539.	4.8	6
77	Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients. Frontiers in Immunology, 2021, 12, 789735.	4.8	23
78	The adaptation of SARS-CoV-2 to humans. Memorias Do Instituto Oswaldo Cruz, 2022, 116, e210127.	1.6	4
79	Single-cell immunology of SARS-CoV-2 infection. Nature Biotechnology, 2022, 40, 30-41.	17.5	78
80	Potential Immune Indicators for Predicting the Prognosis of COVID-19 and Trauma: Similarities and Disparities. Frontiers in Immunology, 2021, 12, 785946.	4.8	7
81	TNFα-Producing CD4 ⁺ T Cells Dominate the SARS-CoV-2-Specific T Cell Response in COVID-19 Outpatients and Are Associated with Durable Antibodies. SSRN Electronic Journal, 0, , .	0.4	0
82	Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV+ Controllers and ART-Suppressed Individuals. Frontiers in Immunology, 2022, 13, 803417.	4.8	12
83	CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects. Frontiers in Immunology, 2021, 12, 755891.	4.8	10
84	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European Journal of Immunology, 2021, 51, 2708-3145.	2.9	198
85	Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies. SSRN Electronic Journal, 0, , .	0.4	0
86	Selection of Optimum Formulation of RBD-Based Protein Sub-Unit Covid19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies. SSRN Electronic Journal, 0, , .	0.4	0
87	T cell responses to SARS-CoV-2 in humans and animals. Journal of Microbiology, 2022, 60, 276-289.	2.8	8
90	Severe Acute Respiratory Syndrome Coronavirus 2 Cross-Reactive B and T Cell Responses in Kidney Transplant Patients, Transplantation Proceedings, 2022, 54, 1455-1464	0.6	3

#	Article	IF	CITATIONS
93	Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe, The, 2022, 3, e252-e264.	7.3	29
94	Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. Molecular Therapy - Methods and Clinical Development, 2022, 25, 52-73.	4.1	11
96	Analysis of TCR Repertoire by High-Throughput Sequencing Indicates the Feature of T Cell Immune Response after SARS-CoV-2 Infection. Cells, 2022, 11, 68.	4.1	12
97	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. Journal of Microbiology and Biotechnology, 2021, 31, 1601-1614.	2.1	8
98	Providing a Helping Hand: Metabolic Regulation of T Follicular Helper Cells and Their Association With Disease. Frontiers in Immunology, 2022, 13, 864949.	4.8	3
99	Assessment of changes in immune status linked to COVID-19 convalescent and its clinical severity in patients and uninfected exposed relatives. Immunobiology, 2022, 227, 152216.	1.9	2
100	T helper cell subsets and related target cells in acute COVID-19. Russian Journal of Infection and Immunity, 2022, 12, 409-426.	0.7	4
101	Immunouniverse of SARS-CoV-2. Immunological Medicine, 2022, 45, 186-224.	2.6	8
102	TNF-α+ CD4+ TÂcells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Reports Medicine, 2022, 3, 100640.	6.5	15
103	Distinct miRNAs associated with various clinical presentations of SARS-CoV-2 infection. IScience, 2022, 25, 104309.	4.1	9
104	Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview. Viruses, 2022, 14, 1082.	3.3	20
106	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Frontiers in Immunology, 0, 13, .	4.8	7
107	Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. Multiple Sclerosis Journal, 2022, 28, 1937-1943.	3.0	6
108	High and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4+ T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19. Viruses, 2022, 14, 1265.	3.3	5
109	The Dynamic Role of FOXP3+ Tregs and Their Potential Therapeutic Applications During SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, .	4.8	13
110	Short and long-term immune changes in different severity groups of COVID-19 disease. International Journal of Infectious Diseases, 2022, 122, 776-784.	3.3	4
111	Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV. ELife, 0, 11, .	6.0	11
112	The deciphering of the immune cells and marker signature in COVIDâ€19 pathogenesis: An update. Journal of Medical Virology, 2022, 94, 5128-5148.	5.0	12

#	Article	IF	CITATIONS
114	Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. International Journal of Biological Sciences, 2022, 18, 4629-4641.	6.4	24
116	T cell perturbations persist for at least 6 months following hospitalization for COVID-19. Frontiers in Immunology, 0, 13, .	4.8	16
117	Humoral and cellular response in convalescent COVID-19 lupus patients. Scientific Reports, 2022, 12, .	3.3	1
118	Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. Nature Communications, 2022, 13, .	12.8	18
119	Angiotensin II Exaggerates SARS-CoV-2 Specific T-Cell Response in Convalescent Individuals following COVID-19. International Journal of Molecular Sciences, 2022, 23, 8669.	4.1	8
120	Adoptive transfer of functional <scp>SARSâ€COV</scp> â€2â€specific immunity from donor graft to hematopoietic stem cell transplant recipients. American Journal of Hematology, 2022, 97, .	4.1	3
121	Heterogenous CD8+ T Cell Maturation and â€~Polarization' in Acute and Convalescent COVID-19 Patients. Viruses, 2022, 14, 1906.	3.3	16
122	In Vitro Stimulation with Live SARS-CoV-2 Suggests Th17 Dominance In Virus-Specific CD4+ T Cell Response after COVID-19. Vaccines, 2022, 10, 1544.	4.4	0
123	Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination. Frontiers in Immunology, 0, 13, .	4.8	4
124	COVIDâ€19 immunopathology: From acute diseases to chronic sequelae. Journal of Medical Virology, 2023, 95, .	5.0	24
125	T-cells in human trigeminal ganglia express canonical tissue-resident memory T-cell markers. Journal of Neuroinflammation, 2022, 19, .	7.2	3
126	The Perspective of Covid-19 Vaccines: What Needs to Be Known and Its Expected Effect on the Human Population?. Journal of Biosciences and Medicines, 2022, 10, 34-46.	0.2	0
127	Coronavirus (COVID-19) and the Human Immunity: A Review. , 0, 14, 281-286.		0
128	Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. Frontiers in Immunology, 0, 13, .	4.8	16
129	Humoral and cellular immune responses to CoronaVac up to one year after vaccination. Frontiers in Immunology, 0, 13, .	4.8	8
130	SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses. AIMS Microbiology, 2022, 8, 422-453.	2.2	1
131	Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2. Vaccines, 2022, 10, 1997.	4.4	4
133	Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination. Journal of Immunology, 2022, 209, 1892-1905.	0.8	7

#	Article	IF	CITATIONS
134	Immune responses in mildly versus critically ill COVID-19 patients. Frontiers in Immunology, 0, 14, .	4.8	18
135	Advances in HIV Research Using Mass Cytometry. Current HIV/AIDS Reports, 0, , .	3.1	0
136	Defending against SARS-CoV-2: The T cell perspective. Frontiers in Immunology, 0, 14, .	4.8	20
138	T Cell Response to SARS-CoV-2 Coinfection and Comorbidities. Pathogens, 2023, 12, 321.	2.8	4
139	Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics. BioImpacts, 0, , .	1.5	0
140	Allogeneic hematopoietic stem cell transplantation in the COVID-19 era. Frontiers in Immunology, 0, 14,	4.8	3
141	Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. Frontiers in Immunology, 0, 14, .	4.8	3
142	Differential regulatory T cell signature after recovery from mild COVID-19. Frontiers in Immunology, 0, 14, .	4.8	2
143	SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. Frontiers in Immunology, 0, 14, .	4.8	1
144	Dynamic changes in radiological parameters, immune cells, selected miRNAs, and cytokine levels in peripheral blood of patients with severe COVID†19. Biomedical Reports, 2023, 18, .	2.0	0
145	Virus-Specific Stem Cell Memory CD8+ T Cells May Indicate a Long-Term Protection against Evolving SARS-CoV-2. Diagnostics, 2023, 13, 1280.	2.6	0
146	COVID-19 Severity Shifts the Cytokine Milieu Toward a Proinflammatory State in Egyptian Patients: A Cross-Sectional Study. Journal of Interferon and Cytokine Research, 2023, 43, 257-268.	1.2	1
147	Low avidity circulating SARS-CoV-2 reactive CD8+ T cells with proinflammatory TEMRA phenotype are associated with post-acute sequelae of COVID-19. Frontiers in Microbiology, 0, 14, .	3.5	4
148	Neuroimmune Mechanisms Underlying Post-acute Sequelae of SARS-CoV-2 (PASC) Pain, Predictions from a Ligand-Receptor Interactome. Current Rheumatology Reports, 0, , .	4.7	1
149	Post-COVID immunopatology syndrome: characteristics of phenotypical changes in the immune system in post-COVID patients. Medical Immunology (Russia), 2023, 25, 791-796.	0.4	1
150	Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates. IScience, 2023, 26, 107224.	4.1	2
151	Considerations for Choosing T Cell Assays during a Pandemic. Journal of Immunology, 2023, 211, 169-174.	0.8	1
152	Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates. Journal of Controlled Release, 2023, 360, 316-334.	9.9	4

CITATION REPORT

ARTICLE IF CITATIONS # Dissecting the Protective Effect of CD8+ T Cells in Response to SARS-CoV-2 mRNA Vaccination and the 153 2.8 4 Potential Link with Lymph Node CD8+ T Cells. Biology, 2023, 12, 1035. Differential Roles of Interleukin-6 in Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and 154 Cardiometabolic Diseases., 0,,. Cross-reactive humoral and CD4+ T cell responses to Mu and Gamma SARS-CoV-2 variants in a 155 4.8 1 Colombian population. Frontiers in Immunology, 0, 14, . Airway Epithelial-Derived Immune Mediators in COVID-19. Viruses, 2023, 15, 1655. 156 mRNA vaccination boosts S-specific TÂcell memory and promotes expansion of CD45RAint TEMRA-like 157 6.5 1 CD8+ TÂcells in COVID-19 recovered individuals. Ćell Reports Medicine, 2023, 4, 101149. Dysregulated metal ion homeostasis underscores non-canonical function of CD8+ T cell during 2.6 COVID-19. Frontiers in Medicine, 0, 10, . 159 Memory T Cells Discrepancies in COVID-19 Patients. Microorganisms, 2023, 11, 2737. 3.6 0 HIIT Induces Stronger Shifts within the Peripheral T Cell Compartment Independent of Sex. 1.7 International Journal of Sports Medicine, 2024, 45, 211-221. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune 161 14.5 3 response to SARS-CoV-2. Nature Immunology, 2024, 25, 218-225. Comparative characteristics of the cellular immune response to SARS-CoV-2 during infection and 0.4 post-vaccination. Medical Immunology (Russia), 2024, 26, 345-354. Anti-synthetase syndrome is associated with a higher risk of hospitalization among patients with 164 0 4.8 idiopathic inflammatory myopathy and COVID-19. Frontiers in Immunology, 0, 15, . Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare 1.4 workers: An observational study. Journal of Immunological Methods, 2024, 528, 113665.

CITATION REPORT